Tamoxifen and its new derivatives in cancer research

Recent Patents on Anti-Cancer Drug Discovery

Volumn 6, Issue 2, 2011, Pages 237-245

  Rivera Guevara, Claudia ^a   Camacho, Javier ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Breast cancer; Estrogen receptor; Gene expression; Ion channels; Tamoxifen; Tamoxifen derivatives; Tamoxifen patents

Indexed keywords

4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; ANTIESTROGEN; ARZOXIFENE; BAZEDOXIFENE; CENTCHROMAN; CLOMIFENE; DROLOXIFEN; ESTROGEN RECEPTOR; ETOPOSIDE; GEFITINIB; IODOXIFENE; LASOFOXIFENE; NAFOXIDINE; ONAPRISTONE; ORMEXIFENE; OSPEMIFENE; RALOXIFENE; TAMOXIFEN; TAMOXIFEN DERIVATIVE; TOREMIPHENE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CANCER RESISTANCE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; NONHUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; THROMBOEMBOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FEMALE; HUMANS; PATENTS AS TOPIC; TAMOXIFEN;

EID: 79954453870     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489211795328486     Document Type: Article

References (112)

1. Jordan VC. Tamoxifen: A most unlikely pioneering medicine. Nat Rev Drug Discov 2003; 2: 205-13.
2. Harper MJ, Walpole AL. A new derivative of triphenylethylene: Effect on implantation and mode of action in rats. J Reprod Fertil 1967; 13: 101-19.
3. Harper MJ, Walpole AL. Contrasting endocrine activities of CIS and trans isomers in a series substituted triphenylethylenes. Nature 1966; 212: 87.
4. Mahoney MC, Bevers T, Linos E, Willett WC. Opportunities and strategies for breast cancer prevention through risk reduction. CA Cancer J Clin 2008; 58: 347-71.
5. Jordan VC. Tamoxifen: Catalyst for the change to targeted therapy. Eur J Cancer 2008; 44: 30-38.
6. Erlander, M.G., Ma, X.-J., Sgroi, D. Predicting outcome with tamoxifen in breast cancer. US7504214 (2009).
7. Huang HJ, Norris JD, McDonnell DP. Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. Mol Endocrinol 2002; 16: 1778-92.
8. McDonnell DP. The molecular determinants of estrogen receptor pharmacology. Maturitas 2004; 48: 7-12.
9. Otto A, Paddenberg R, Schubert S, Mannhertz H. Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin. J Cancer Res Clin Oncol 1996; 22: 603-12.
10. Drouin, D. S,. Wepierre, J. Percutaneous composition comprising 4-hydroxy tamoxifen. US7704516 (2010).
11. Rouanet, P., Drouin, D. S., Wepierre, J. Prevention and treatment of breast cancer with 4-hydroxy tamoxifen US20090186944 (2009).
12. Ahmad, A., Ali, S.M., Ahmad, M.U., Sheikh, S., Ahmad, I. Endoxifen compositions and methods. US20100112041 (2010).
13. Bua, J., Reduction of breast density with 4-hydroxy tamoxifen. EP1572171 (2009).
14. de Lignières, B. Treatment of mastalgia with 4-hydroxy tamoxifen. US7786172 (2010).
15. Perry R, Kang Y, Greaves B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and-independent human breast cancer cells. Ann Surg Oncol 1995; 2: 238-45.
16. Jordan VC. Tamoxifen (ICI 46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol 2006; 147: 269-76.
17. Barakat RR. Tamoxifen and endometrial neoplasia. Clin Obstet Gynecol 1996; 39: 629-40.
18. Barakat RR. Tamoxifen and the endometrium. Cancer Treat Res 1998; 94: 195-207.
19. Sato M, Glasebrook AL, Bryant HU. Raloxifene: A selective estrogen receptor modulator. J Bone Miner Metab 1994; 12: 9-20.
20. Toivola, R.J., Karjalainen, A.J., Kurkela, K.O.A., Soderwall, M-L., Kangas, L.V.M., Blanco, G.L., Sunduiqst, H.K. Novel tri-phenyl alkane and alkene derivatives and their preparation and use. US4696949 (1987).
21. Double, J., Maitland, D., Popa, I. Tamoxifen and analogues thereof. US6172263 (2001).
22. Palopoli, F.P., Feil, V.J. Substituted diphenyl ketones. US3244705 (1966).
23. Wallace OB, Richardson TI, Dodge JA. Estrogen receptor modulators: Relationships of ligand structure, receptor affinity and functional activity. Curr Top Med Chem 2003; 3: 1663-80.
24. Meegan MJ, Lloyd DG. Advances in the science of estrogen receptor modulation. Curr Med Chem 2003; 10: 181-210.
25. Liu X, Pisha E, Tonetti DA, Yao D, Li Y, Yao J, et al. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites. Chem Res Toxicol 2003; 16: 832-37.
26. Yang, D.J., Wallace, S. High affinity tamoxifen derivatives and uses therof. US5192525 (1993).
27. Mccague, R. Iodotamoxifen derivatives and use for estrogen receptor-positive breast cancer detection and therapy. US4839155 (1989).
28. Yang, D.J., Wallace, S. High affinity halogenated-tamoxifen derivatives and uses thereof. US5219548 (1993).
29. Wallace, S., Yang, D.J., Deplessand, E., Cherif, A., Quadri, S. High affinity tamoxifen derivatives. US6096874 (2000).
30. Khoza T, Hosie M. Clomiphene citrate modulates the expression of endometrial carbohydrates (especially N-acetyl-D-glucosamine and sialic acid) in pseudopregnant rats. Theriogenology 2008; 70: 612-21.
31. Bitonti, A.J., Baumann, R.J. Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors. US5410080 (1995).
32. Eppenberger U, Wosikowski K, Kung W. Pharmacologic and biologic properties of droloxifene, a new antiestrogen. Am J Clin Oncol 1991; 14: 5-14.
33. Huang Y, Shen Y, Feng Y, Cao L, Leng Y. Anti-implantation effect of droloxifene in rats and its relationship with anti-estrogenic activity. Acta Pharmacol Sin 2005; 10: 1243-47.
34. Weatherman RV, Clegg NJ, Scanlan TS. Differential SERM activation of the estrogen receptors (ER_ and ER_) at AP-1 sites. Chem Biol 2001; 8: 427-36.
35. Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R. Ylikorkala effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: A double-blind, randomized trial. Menopause 2003; 10: 399-433.
36. Ylikorkala O, Cacciatore B, Halonen K, Lassila R, Lammintausta R, Rutanen EM, et al. Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women. Menopause 2003; 10: 440-47.
37. Bryant, H.U., Fuchs-Young, R.S.L. Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs. US5691355 (1997).
38. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641-7.
39. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445-51.
40. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [erratum in JAMA 1999; 282: 2124]. JAMA 1999; 282: 637-45.
41. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281: 2189-97.
42. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple Outcomes of Raloxifene Evaluation. Breast Cancer Res Treat 2001; 65: 125-34.
43. Jordan VC. Tamoxifen or raloxifene for breast cancer chemoprevention: A tale of two choices point. Cancer Epidemiol Biomarkers 2007; 16: 2207-9.
44. Lee WL, Cheng MH, Chao HT, Wang PH. The role of selective estrogen receptor modulators on breast cancer: From tamoxifen to raloxifene. Taiwan J Obstet Gynecol 2008; 47: 24-31.
45. Jordan VC. SERMs: Meeting the promise of multifunctional medicines. J Natl Cancer Inst 2007; 99: 350-6.
46. Suh N, Glasebrook AL, Palkowitz AD, Bryant HU, Burris LL, Starling JJ, et al. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res 2001; 61: 8412-15.
47. Qin Z, Kastrati I, Ashgodom RT, Lantvit DD, Overk CR, Choi YS, et al. Structural modulation of oxidative metabolism in design of improved benzothiophene selective estrogen receptor modulators. Drug Metab Dispos 2009; 37: 161-9.
48. Yu B, Dietz BM, Dunlap T. Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: Induction of chemopreventive mechanisms. Mol Cancer Ther 2007; 6: 2418-28.
49. Ning N, Zhou C, Weng J, Zhang S, Chen D, Yang C, et al. Biological activities of a novel selective oestrogen receptor modulator derived from raloxifene (Y134). Br J Pharmacol 2007; 150: 19-28.
50. Safe, S.F. Indole-3-carbinol, diindolyimethane and substituted analogs as antiestrogens. US948808 (1999).
51. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. Bazedoxifene acetate: A selective estrogen receptor modulator with improved selectivity. Endocrinology 2005; 146: 3999-4008.
52. Bryant, H.U., Fuchs-Young, R.S.L. Method for inhibiting mammalian breast carcinoma with tamoxifen, and analogs thereof, and certain naphthyl compounds. US5658931 (1997).
53. Lewiecki EM. Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis. Ther Clin Risk Manage 2009; 5: 817-27.
54. Yaz G, Kabadere S, Oztopçu P, Durmaz R, Uyar R. Comparison of the antiproliferative properties of antiestrogenic drugs (nafoxidine and clomiphene) on glioma cells in vitro. Am J Clin Oncol 2004; 27: 384-8.
55. Kumar S, Deshpande S, Chandra V, Kitchlu S, Dwivedi A, Nayak VL, et al. Synthesis and biological evaluation of 2,3,4-triarylbenzopyran derivatives as SERM and therapeutic agent for breast cancer. Bioorg Med Chem 2009; 17: 6832-40.
56. Mountfield RJ, Kiehr B, John BA. Metabolism disposition, excretion, and pharmacokinetics of levormeloxifene, a selective estrogen receptor modulator, in the rat. Drug Metab Dispos 2000; 28: 503-13.
57. Alexandersen P, Riis BJ, Stakkestad JA, Delmas PD, Christiansen C. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy. J Clin Endocrinol Metab 2001; 86: 755-60.
58. Chandra BS, Kumar SS, Shankar BT, Chandra GRS, Chandra RA, Prasad KS. Ormeloxifene a selective estrogen modulator, for treatment of dysfunctional menorrhagia. J Obstet Gynecol Ind 2004; 54: 56-9.
59. Shankar R, Chakravarti B, Singh US, Ansari MI, Deshpande S, Dwivedi SKD, et al. Synthesis and biological evaluation of 3,4,6-triaryl-2-pyranones as a potential new class of anti-breast cancer agents. Bioorg Med Chem 2009; 17: 3847-56.
60. Nikitin K, Ortin Y, Müller-Bunz H, Plamont MA, Jaouen G, Vessieres A, et al. Organometallic SERMs (selective estrogen receptor modulators): Cobaltifens, the (cyclobutadiene) cobalt analogues of hydroxytamoxifen. J Organomet Chem 2010; 695: 595-608.
61. Zanellato I, Heldt JM, Vessières A, Jaouen G, Osella D. Antiproliferative effect of ferrocifen drug candidates on malignant pleural mesothelioma cell lines. Inorg Chim Acta 2009; 362: 4037-42.
62. Gupta A, Mandal SK, Leblanc V, Descoteaux C, Asselin E, Berube G. Synthesis and cytotoxic activity of benzopyran-based platinum(II) complexes. Bioorg Med Chem Lett 2008; 18: 3982-7.
63. Jordan VC. A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: The origins of targeted therapy and chemoprevention. Cancer Res 2009; 69: 1243-54.
64. Goss PE, Qi S, Hu H. Comparing the effects of atamestane, toremifene and tamoxifen alone and in combination, on bone, serum lipids and uterus in ovariectomized rats. J Steroid Biochem Mol Biol 2009; 113: 233-40.
65. Hughes-Davies L, Caldas C, Wishart GC. Tamoxifen: The drug that came in from the cold. Br J Cancer 2009; 101: 875-8.
66. Mimeault M, Venkatramanl G, Johansson SL, Moore E, Henichart JP, Depreux P, et al. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. Int J Cancer 2007; 120: 160-9.
67. Okubo S, Kurebayashi J, Otsuki T, Yamamoto Y, Tanaka K, Sonoo H. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. Br J Cancer 2004; 90: 236-44.
68. Shen H, Yuan Y, Sun J, Gao W, Shu YQ. Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Biomed Pharmacother 2010; 64: 88-92.
69. Nishino T, Ishibashi K, Hirtreiter C, Nishino Y. Potentiation of the antitumor effect of tamoxifen by combination with the antiprogestin onapristone. J Steroid Biochem Mol Biol 2009; 116: 187-90.
70. Giovannia CD, Nicoletti G, Landuzzi L. Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy. Vaccine 2009; 27: 2065-9.
71. McClay EF, Mastrangelo MJ, Sprandio DJ, Bellet RE, Berd D. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 1989; 63: 1292-5.
72. Scambia G, Ranelletti FO, Panici PB, Piantelli M, Devincenzo R, Bonanno G, et al. Synergistic antiproliferative activity of tamoxifen and cisplatin on primary ovarian tumours. Eur J Cancer 1992 11: 1885-9.
73. Leonessa F, Jacobson M, Boyle B, Lippman J, Mcgarvey M, Clarke R. Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: Isobologram, drug accumulation and Mr 170 000 glycoprotein (gp170) binding studies. Cancer Res 1994; 54: 441-7.
74. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, et al. High-dose oral tamoxifen, a potential multidrugresistance-reversal agent: Phase I trial in combination with vinblastine. J Natl Cancer Inst 1992; 84: 1811-6.
75. Ferlini C, Scambia G, Distefano M, Filippini P, Isola G, Riva A, et al. Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis. Br J Cancer 1997; 75: 884-91.
76. Ferlini C, Scambia G, Marone M, Distefano M, Gaggini C, Ferrandina G, et al. Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. Br J Cancer 1999; 79: 257-63.
77. Kim JA, Kang YS, Jung MW, Lee SH, Lee YS. Involvement of Ca influx in the mechanism of tamoxifen-induced apoptosis in HepG2 human hepatoblastoma cells. Cancer Lett 1999: 147:115-23.
78. Lam L, Hu X, Aktary Z, Andrews DW, Pasdar M. Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ER _. Breast Cancer Res Treat 2009; 118(3): 605-21.
79. Zhang W, Couldwell WT, Song H, Takano T, Lin JH, Nedergaard M. Tamoxifen-induced enhancement of calcium signaling in glioma and MCF-7 breast cancer cells. Cancer Res 2000; 60: 5395-400.
80. Lehenkari P, Parikka V, Rautiala TJ, Weckstrom M, Dahllund J, Harkonen PL, et al. The effects of tamoxifen and toremifene on bone cells involve changes in plasma membrane ion conductance. J Bone Miner Res 2003; 18: 473-8.
81. Couldwell WT, Hinton DR, He S. Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett 1994; 345: 43-6.
82. Gelmann EP. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin Oncol 1997; 24: 65-70.
83. Chen HM, Tritton TR, Kenny N, Absher M, Chiu JF. Tamoxifen induces TGF _1 activity and apoptosis of human MCF-7 breast cancer cells in vitro. J Cell Biochem 1996; 61: 9-17.
84. Osbourne CK, Boldt DH, Clark GM, Trent JM. Effects of tamoxifen on human breast cancer cell cycle kinetics: Accumulation of cells in early G1 phase. Cancer Res 1983; 43: 3583-5.
85. Perry RR, Kang Y, Greaves B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and-independent human breast cancer cells. Ann Surg Oncol 1995; 2: 238-45.
86. Otto AM, Paddenberg R, Schubert S, Mannherz HG. Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin. J Cancer Res Clin Oncol 1996; 22: 603-12.
87. Heerdt AS, Borgen PI. Current status of tamoxifen use: An update for the surgical oncologist. J Surg Oncol 1999; 72: 42-9.
88. 2 and inorganic phosphate. Toxicol Appl Pharmacol 1998; 152: 10-7.
89. Cardoso CM, Custodio JB, Almeida LM, Moreno AJ. Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency. Toxicol Appl Pharmacol 2001; 176: 145-52.
90. Cardoso CM, Moreno AJ, Almeida LM, Custodio JB. Comparison of the changes in adenine nucleotides of rat liver mitochondria induced by tamoxifen and 4-hydroxytamoxifen. Toxicol In Vitro 2003; 17: 663-70.
91. Zheng A, Kallio A, Härkönen P. Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signalregulated kinase signaling and can be abrogated by estrogen. Endocrinology 2007; 148: 2764-77.
92. Dietze EC, Caldwell LE, Grupin SL, Mancini M, Seewaldt VL. Tamoxifen but not 4-hydroxytamoxifen initiates apoptosis in p53(-) normal human mammary epithelial cells by inducing mitochondrial depolarization. J Biol Chem 2001; 276: 5384-94.
93. Schwartz Z, Sylvia VL, Guinee T, Dean DD, Boyan BD. Tamoxifen elicits its anti-estrogen effects in growth plate chondrocytes by inhibiting protein kinase C. J Steroid Biochem Mol Biol 2002; 80: 401-10.
94. Duh JL, Yu R, Jiao JJ, Matwyshyn GA, Li W, Tan TH, et al. Activation of signal transduction kinases by tamoxifen. Pharm Res 1997; 14:186-9.
95. Adamski J, Benveniste E. 17ß-Estradiol activation of the C-jun NTerminal kinase pathway leads to down-regulation of class II major histocompatibility complex expression. Mol Endocrinol 2005; 19: 113-24.
96. Boyan BD, Sylvia VL, Frambach T, Frambach T, Lohmann CH, Dietl J, et al. Estrogen-dependent rapid activation of protein kinase C in estrogen receptor positive MCF-7 breast cancer cells and in estrogen-receptor negative HCC38 cells is membrane-mediated and inhibited by tamoxifen. Endocrinology 2003; 144: 1812-24.
97. Kallio A, Zheng A, Dahllund J, Heiskanen KM, Härkönen P. Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. Apoptosis 2005; 10: 1395-410.
98. Lee T-H, Chuang L-Y, Hung W-C. Tamoxifen induces p21WAF1 and p27KIP1 expression in estrogen receptor-negative lung cancer cells. Oncogene 1999; 18: 4269-74.
99. Bolanz KA, Kovacs GG, Landowski CP, Hediger MA. Tamoxifen inhibits TRPV6 activity via estrogen receptor-independent pathways in TRPV6-expressing MCF-7 breast cancer cells. Mol Cancer Res 2009; 12: 2000-10.
100. Lehen'kyi V, Flourakis M, Skryma R, Prevarskaya N. TRPV6 channel controls prostate cancer cell proliferation via Ca(2+)/NFAT-dependent pathways. Oncogene 2007; 52: 7380-5.
101. Bolanz KA, Hediger MA, Landowski CP. The role of TRPV6 in breast carcinogenesis. Mol Cancer Ther 2008; 2: 271-9.
102. Hu H, Li DL, Fan L, Ren J, Wang SP, Jia B, et al. Involvement of volume-sensitive Cl channels in the proliferation of human subcutaneous pre-adipocytes. Clin Exp Pharmacol Physiol 2010; 1: 29-34.
103. Li M, Wang Q, Lin W, Wang B. Regulation of ovarian cancer cell adhesion and invasion by chloride channels. Int J Gynecol Cancer 2009; 4: 526-30.
104. Afrasiabi E, Hietamäki M, Viitanen T, Sukumaran P, Bergelin N, Törnquist K. Expression and significance of HERG (KCNH2) potassium channels in the regulation of MDA-MB-435S melanoma cell proliferation and migration. Cell Signal 2010; 1: 57-64.
105. Dolderer JH, Schuldes H, Bockhorn H, Altmannsberger M, Lambers C, von Zabern D, et al. HERG1 gene expression as a specific tumor marker in colorectal tissues. Eur J Surg Oncol 2010; 36: 72-7.
106. Bianchi L, Wible B, Arcangeli A, Taglialatela M, Morra F, Castaldo P, et al. Herg encodes a K+ current highly conserved in tumors of different histogenesis: A selective advantage for cancer cells? Cancer Res 1998; 58: 815-22.
107. Thomas D, Gut B, Karsai S, Wimmer AB, Wu K, Wnedt-Nordhal G, et al. Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen. Naunyn-Schmiedeberǵs Arch Pharmacol 2003; 368: 41-8.
108. Stavrovskaya AA, Stromskaya TP. Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry (Moscow) 2008; 73: 592-604.
109. Katzenellenbogen BS. Antiestrogen resistance: Mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. J Natl Cancer Inst 1991; 83: 1434-5.
110. Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005; 11: 865-70.
111. Agthoven TV, Sieuwerts AM, Meijer-van Gelder M, Look MP, Smid M, Veldscholte J, et al. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol 2009; 27: 542-9.
112. Rivera-Guevara C, Pérez-Alvarez V, García-Becerra R, Ordaz-Rosado D, Morales-Ríos MS, Hernández-Gallegos E, et al. Genomic action of permanently charged tamoxifen derivatives via estrogen receptor-alpha. Bioorg Med Chem 2010; 15: 5593-601.